Table 4.
Propensity score weighted analysis on complete CINV response from days 1 to 5
| Variables1 | Odds ratio2 | 95%CI | Impact on CINV complete response |
|---|---|---|---|
| NK1 group (vs. CINVANTI®) | |||
| IV EMEND® | 1.00 | (0.54 to 1.86) | NS |
| Generic alternatives | 1.12 | (0.54 to 2.32) | NS |
| Cycle 1 vs. ≥ cycle 2 | 0.44 | (0.29 to 0.55) | ↓ likelihood by 56% |
| Breast vs. other cancers | 0.27 | (0.16 to 0.48) | ↓ likelihood by 73% |
| Female sex | 0.37 | (0.14 to 0.95) | ↓ likelihood by 63% |
| IV fluid rate ≥ 100 mL/h | 0.20 | (0.10 to 0.37) | ↓ likelihood by 80% |
| Dexamethasone added to IV bag | 6.42 | (3.1 to 13.5) | ↑ likelihood by 6.42 times |
| Adjusted R^2 statistic3 | 23.6% | ||
Dependent variable: complete control of CINV from days 1 to 5 post chemotherapy
Abbreviations: NK1 neurokinin 1 receptor antagonist, CINV chemotherapy-induced nausea and vomiting, NS not significant
1These are the final variables that were retained following the application of the likelihood ratio test (p < 0.05 to retain) in a backwards elimination process
2An odds ratio of less than one indicates lower likelihood and greater than one an increased likelihood
3This is the proportion of variability in the dependent variables than is accounted for by the independent variables